Fatty Liver Is a Cardiovascular Disease in Disguise

The condition now goes by an unlovely acronym: MASLD, for metabolic dysfunction-associated steatotic liver disease. (You may remember it by its older name, NAFLD — non-alcoholic fatty liver disease.) A 2025 review in Clinical and Experimental Hepatology describes it as the most common chronic liver disease in the world, affecting about 30% of adults and roughly 10% of children. Those numbers may be undercounts — MASLD is famously quiet, often producing no symptoms until something else, like a routine blood panel or an ultrasound for a different complaint, flags it.

What's changing is not the prevalence of fatty liver but the company it keeps. The same review names MASLD outright as an important cardiovascular risk factor, and frames it inside a familiar cluster of weight-dependent problems: insulin resistance, prediabetes, type 2 diabetes, lipid disorders, hypertension. If you've ever seen the words "metabolic syndrome" on a lab printout, MASLD lives in that neighborhood.

Here is the part that reframes the whole conversation. A 2025 cross-sectional study in the Middle East Journal of Digestive Diseases looked at 200 patients with coronary artery disease who were headed for angiography, then measured both their fatty-liver severity (by ultrasound) and their carotid arteries (by Doppler). The carotids are the big vessels in your neck that feed the brain; narrowing there is one of the markers cardiologists watch closely.

The pattern was striking. Among patients with carotid stenosis, 44% had grade 2–3 fatty liver, compared with 19% of patients without stenosis. Higher scores on the FIB-4 index — a simple blood-test-based estimate of liver scarring — tracked with more severe coronary involvement and a higher prevalence of carotid narrowing. This is a single cross-sectional study, not proof of cause and effect, and the patients were already known to have heart disease. But it adds to a body of work suggesting that the inflamed, fibrotic liver is not minding its own business — it appears to be part of the same vascular story.

If you're reading this between feedings, here is the version that fits on a sticky note: the drivers of fatty liver are the drivers of heart disease. The review authors are direct about this — the foundation of prevention and treatment is weight reduction through diet and regular physical activity, plus management of the cardiometabolic factors: diabetes, lipid disorders and hypertension. Drug therapy aimed at the liver itself, they note, remains limited; many candidates are still in clinical trials.

That's not a thrilling headline, but it is a kind one. It means the small, ordinary things — a 20-minute walk with the stroller, swapping one ultra-processed snack for something with fiber, not skipping the boring annual check-in with your GP — are doing real work on more than one organ at once. You are not behind because you haven't optimized a supplement stack. The evidence base is moderate, not miraculous; the levers are familiar.

There's a related strand of this story for anyone who has been treated for hepatitis C. Modern antivirals clear the virus in the great majority of cases, but a 2025 expert position statement in Clinical and Experimental Hepatology argues that the cardiometabolic aftermath needs its own care plan. The authors note that HCV is now considered a new, non-classical cardiovascular risk factor, and that the constellation of obesity, insulin resistance, diabetes, lipid problems and fatty liver that follows infection is significant enough to have its own name: metabolic-viral syndrome. Their recommendations focus on hypolipidemic and antithrombotic therapy in patients treated with direct-acting antivirals, with attention to drug interactions. It's a specialist document, but the takeaway for the rest of us is the same: clearing the virus is the start of the conversation, not the end.

None of this is a verdict. The evidence connecting fatty liver to cardiovascular disease is growing and increasingly hard to ignore, but much of it — including the carotid study above — is observational, and the disease-modifying drug story is still being written. What has shifted is the framing. A generation ago, fatty liver was the thing your doctor mentioned in passing on the way out of the room. Today, the people who study it are asking whether it belongs on the same page as your blood pressure and your cholesterol.

For a tired parent, that reframing is, oddly, good news. It means the work you might already be trying to do — sleep when you can, move when you can, eat something that didn't come out of a foil pouch — counts toward more than one ledger. Pour the second coffee. Text your friend back. Tell her it's worth a conversation with her doctor, not a spiral at 2 a.m.